Free Trial
NASDAQ:PHAR

Pharming Group (PHAR) Stock Price, News & Analysis

Pharming Group logo
$8.91
+0.05 (+0.56%)
(As of 10/31/2024 ET)

About Pharming Group Stock (NASDAQ:PHAR)

Key Stats

Today's Range
$8.40
$8.91
50-Day Range
$6.99
$9.13
52-Week Range
$6.65
$13.20
Volume
6,628 shs
Average Volume
4,857 shs
Market Capitalization
$604.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.50
Consensus Rating
Buy

Company Overview

Pharming Group N.V. is a Dutch biotech company specializing in developing innovative therapies for rare diseases. The company aims to improve patients' lives suffering from debilitating illnesses by developing and commercializing safe and effective treatments.

Pharming's lead product is Ruconest, a recombinant human C1 esterase inhibitor indicated for the treatment of hereditary angioedema (HAE) attacks. HAE is a rare and life-threatening genetic disorder that causes swelling in various body parts, including the hands, feet, face, and airways. Ruconest is the only recombinant C1 inhibitor approved by the FDA and EMA for the treatment of acute attacks of HAE in adults and adolescents.

The company's target market is patients suffering from HAE, which is estimated to affect approximately 1 in 10,000 to 1 in 50,000 people worldwide. The key customers for Ruconest are hospitals, clinics, and specialized treatment centers that provide care for patients with HAE.

Pharming is headquartered in Leiden, Netherlands, with additional offices in the United States and Switzerland. The company was founded in 1986 and went public on Euronext Amsterdam in 1999. In 2019, the company established a US subsidiary and started trading on the NASDAQ Global Market.

Pharming has achieved several key milestones in recent years. In 2019, the FDA approved Ruconest for treating acute attacks of HAE in pediatric patients, expanding the drug's market potential. In 2020, the company received a $10 million milestone payment from its partner, Kyowa Kirin, for the achievement of a sales target for Ruconest in Japan.

Sijmen de Vries is the Chief Executive Officer of Pharming and has been with the company since 2009. He has over 30 years of experience in the pharmaceutical industry, including leadership positions at Genzyme, AstraZeneca, and Schering-Plough.

Pharming reported revenue gradually increasing yearly over the past several years. The company's gross profit margin is around 80%, reflecting the high profitability of its products. Pharming has a manageable debt load with plenty of assets to cover liabilities. 

The company's revenue growth can be attributed to the strong performance of Ruconest, which generated sales of over $150 million a year for the past several years. The company also saw growth in its pipeline of products, with its new recombinant factor VIII product, RUCONEST® (human C1 esterase inhibitor) for treating acute HAE, receiving marketing authorization from the European Commission in 2021.

Pharming's valuation metrics are generally in line with its peers in the biotech industry. The company's price-to-earnings ratio is higher than the industry average. The company's price-to-book ratio is also higher than the industry average. These and other valuation metrics could mean investors see the stock as overvalued. 

The rare disease market is growing and lucrative, with an estimated 400 million worldwide suffering from rare diseases. The market for HAE treatments is expected to reach $2.7 billion by 2025, driven by the increasing prevalence of the disease and the introduction of new therapies.

Pharming faces competition from other biotech companies developing therapies for HAE, such as Takeda Pharmaceutical Company Limited and CSL Behring. However, Ruconest has demonstrated superior safety and efficacy compared to other C1 esterase inhibitors in clinical trials, giving the company a competitive advantage.

Pharming's pipeline includes promising products, such as RUCONEST® for treating acute HAE and Leniolisib for treating PIK3CA-related overgrowth spectrum (PROS). The company is also exploring new indications for Ruconest, such as treating pre-eclampsia and COVID-19.

Pharming has also recently announced plans to expand its manufacturing capacity with a new facility in the Netherlands. The new facility is expected to increase its production capacity and reduce reliance on third-party manufacturers, improving its gross margins and overall profitability.

The biotech industry is subject to regulatory and clinical risks, as the approval and commercialization of new products are dependent on regulatory agencies' decisions and successful clinical trials. Changes in reimbursement policies or the introduction of competing therapies could also impact the company's revenue growth.

Pharming also depends on the success of Ruconest, as it represents the majority of the company's revenue. Any unexpected safety concerns or competitive pressures could significantly impact the company's financial performance.

Pharming Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
48th Percentile Overall Score

PHAR MarketRank™: 

Pharming Group scored higher than 48% of companies evaluated by MarketBeat, and ranked 647th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pharming Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pharming Group has only been the subject of 2 research reports in the past 90 days.

  • Read more about Pharming Group's stock forecast and price target.
  • Earnings Growth

    Earnings for Pharming Group are expected to grow in the coming year, from ($0.15) to $0.10 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pharming Group is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pharming Group is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pharming Group has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pharming Group's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Pharming Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Pharming Group has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pharming Group has recently increased by 121.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pharming Group does not currently pay a dividend.

  • Dividend Growth

    Pharming Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Pharming Group have been sold short.
  • Short Interest Ratio / Days to Cover

    Pharming Group has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pharming Group has recently increased by 121.95%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pharming Group has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Pharming Group this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for PHAR on MarketBeat in the last 30 days.
  • MarketBeat Follows

    7 people have added Pharming Group to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pharming Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.07% of the stock of Pharming Group is held by insiders.

  • Percentage Held by Institutions

    Only 0.03% of the stock of Pharming Group is held by institutions.

  • Read more about Pharming Group's insider trading history.
Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Stock News Headlines

Oppenheimer Lowers Pharming Group (NASDAQ:PHAR) Price Target to $30.00
HC Wainwright Forecasts Lower Earnings for Pharming Group
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Pharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?
See More Headlines

PHAR Stock Analysis - Frequently Asked Questions

Pharming Group's stock was trading at $11.43 on January 1st, 2024. Since then, PHAR shares have decreased by 22.0% and is now trading at $8.91.
View the best growth stocks for 2024 here
.

Pharming Group (NASDAQ:PHAR) released its earnings results on Thursday, August, 1st. The company reported ($0.01) EPS for the quarter. The firm had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative trailing twelve-month return on equity of 7.65% and a negative net margin of 6.09%.

Top institutional investors of Pharming Group include Silverberg Bernstein Capital Management LLC (0.06%).

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Sunworks (SUNW), Applied DNA Sciences (APDN), AstraZeneca (AZN) and Costco Wholesale (COST).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/13/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHAR
Fax
N/A
Employees
382
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.50
High Stock Price Target
$37.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+279.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-10,550,000.00
Pretax Margin
-6.04%

Debt

Sales & Book Value

Annual Sales
$285.75 million
Cash Flow
$0.10 per share
Book Value
$3.26 per share

Miscellaneous

Free Float
66,431,000
Market Cap
$598.98 million
Optionable
Not Optionable
Beta
0.15
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:PHAR) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners